Featured Clinical Leader Editorial
-
Why Is Clinical Finance So Challenging?
2/14/2024
IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan explains why the role of clinical finance can be so challenging to define, uphold, and even defend in the world of clinical research.
-
Making Rare Disease Progress With Novel Strategies, Data Standardization, And More
2/14/2024
The integration of innovative research methodologies, coupled with the standardization of data and use of advanced visualization techniques, represents a holistic strategy to address the complexities of rare diseases.
-
4 Things I’m Looking Forward To At SCOPE 2024
2/1/2024
The Summit for Clinical Ops Executives (SCOPE) begins Feb. 11. Discover four things Executive Editor Abby Proch is looking forward to at the annual event.
-
The Impact Of Protocol Design On An IRT System
1/31/2024
DTP and home treatment studies can get expensive — and be a hassle to patients — if the IRT element isn’t well planned for during trial design. In their SCOPE Summit presentation, Irina Grishina and Kelsey Kern of CSL Behring plan to share their personal anecdotes and lessons learned from both types of trials as they pertain to IRT.
-
What Is Clinical Trial Tokenization?
1/30/2024
Tokenization in clinical trials is still a new concept to many sponsors — and their patients who are volunteering for the studies. At his SCOPE Summit presentation, Tom Dougherty of Pfizer will explain this concept and discuss what trials are a fit.
-
Digitizing The Clinical Protocol: Small Steps For Seismic Change
1/30/2024
A proliferation of clinical trial platform systems has meant increased friction for data exchange. Discover how TransCelerate is tackling this problem with small steps that yield big results.
-
A Closer Look At How RBQM Has Evolved In Recent Years
1/29/2024
Mary Arnould, senior director, program management/RBM lead, Clinical Science Operations at Astellas, talks about her SCOPE Summit 2024 presentation called “COVID-19 Pandemic Impact on Risk-Based Quality Management.”
-
FDA Draft Guidance On “Rare Diseases: Considerations For The Development Of Drugs And Biological Products”
1/26/2024
Accenture Applied Life Science Solutions' Raj Bandaru, Ph.D. breaks down, summarizes, and shares detailed insight on the recent FDA Draft Guidance that addresses “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”
-
3 Ways Biotechs Can Lower The Cost Of Clinical Trials
1/23/2024
LongeVC has identified three innovative models to help biotechs lower the cost of their clinical trials.
-
Understanding Precision Neuroscience As Treatment For Rare Autoantibody Disease
1/19/2024
J&J Innovative Medicine develops precision therapeutics in neuroscience, reducing the trial participation and treatment burdens on people living with generalized myasthenia gravis.